抗人膀胱癌免疫毫微球的制备及活性检测  

Monoclonal antibody against human bladder cancer linked with adriamycin loaded human albumin nanospheres and its cytotoxic effects

作　　者：布卡[1] 盛洁 谢蜀生[1] 魏树礼 

机构地区：[1]北京医科大学免疫学系,100083 [2]药学院药剂教研室

出　　处：《中华微生物学和免疫学杂志》1996年第1期54-57,共4页Chinese Journal of Microbiology and Immunology

摘　　要：人膀胱癌单克隆抗体ＢＤＩ－１通过异型双功能交联剂ＳＰＤＰ与载阿霉素人血清白蛋白毫微球偶联，制备了免疫毫微球ＤＢＩ－１－ＨＳＡ（ＡＤＲ）－ＮＳ。此免疫毫微球在体外对人膀胱场细胞ＢＩＵ－８７及Ｅ－Ｊ有特异杀伤效应，而对人直肠癌细胞Ｌｏｖｏ无杀伤；荷瘤裸鼠体内实验表明，此免疫毫微球可明显抑制人膀胱癌细胞的生长。Immunonanospheres (BDI-1-HSA (ADR ) -NS) against human bladder tumor cell lines were constructed by covalently cross linking the monoclonal antibody BDI-1 with adriamycin loaded human. serum albumin nanospheres via hetero bifunctional crosslinker SPDP.BDI-1-HSA (ADR)-NS exerted the specific cytotoxic effects on the target cells human bladder tumor cell lines BIU-87 and E-J , but not on the non target cells human colon carcinomar cell line Lovo. The results of the inhibitory activity of the immunonanospheres on the human bladder cell lines E-J in nude mice xenograft model ,showed that the immunonanospheres could postpone the time of carcinogenesis and reduce the growth of tumor significantly. The therapeutic effect of the immunononanospheres on the tumor , in nude mice xenograft model , was significantly superior to the normal saline and the mixture of BDI- 1 and ADR-HSA-N S.

关 键 词：免疫毫微球 单克隆抗体 膀胱癌 阿霉素 

分 类 号：R392－33[医药卫生—免疫学] R737.14[医药卫生—基础医学]